Recent blog posts
Oscotec/ ADEL reveal FDA has granted the IND application clearance for ADEL-Y01 to treat Alzheimer's Disease
Latest Hotspot
3 min read
Oscotec/ ADEL reveal FDA has granted the IND application clearance for ADEL-Y01 to treat Alzheimer's Disease
20 September 2023
Oscotec Inc. and ADEL Inc. has announced that the FDA has given the IND application approval for ADEL-Y01 to be used in the treatment of Alzheimer's Disease.
Read →
Nektar Therapeutics Reports Encouraging Preliminary Results from Phase 1b Trial of Rezpegaldesleukin
Latest Hotspot
3 min read
Nektar Therapeutics Reports Encouraging Preliminary Results from Phase 1b Trial of Rezpegaldesleukin
20 September 2023
Nektar Therapeutics disclosed fresh clinical results concerning rezpegaldesleukin utilised for patients battling atopic dermatitis, featuring new clinical effectiveness parameters from its Phase 1b research.
Read →
Coeptis Therapeutics provides update on DVX201's Phase 1 Trials safety and dosage for Relapsed/Refractory AML or High Risk MDS patients
Latest Hotspot
3 min read
Coeptis Therapeutics provides update on DVX201's Phase 1 Trials safety and dosage for Relapsed/Refractory AML or High Risk MDS patients
20 September 2023
Coeptis Therapeutics delivers an update on the safety and dosage from Phase 1 Trials of DVX201, intended for those with Relapsed/Refractory AML or High Risk MDS.
Read →
Alzheon Announces Clinical Advances Therapy in Phase 2 Study of ALZ-801  Administered Orally to Early Alzheimer's Patients
Latest Hotspot
4 min read
Alzheon Announces Clinical Advances Therapy in Phase 2 Study of ALZ-801 Administered Orally to Early Alzheimer's Patients
20 September 2023
Alzheon, Inc. reported that their Phase 2 study of ALZ-801 resulted in reduced neural degradation, stabilized brain function, and improved cognition in initial Alzheimer's patients with the apolipoprotein ε4 allele over two years of treatment.
Read →
The initiation patient treatment in Phase 2 clinical trials of Bempikibart for Alopecia Areata has been announced by Q32 Bio and Horizon Therapeutics plc
Latest Hotspot
3 min read
The initiation patient treatment in Phase 2 clinical trials of Bempikibart for Alopecia Areata has been announced by Q32 Bio and Horizon Therapeutics plc
20 September 2023
IQ32 Bio and Horizon Therapeutics initiated a Phase 2 trial for bempikibart's effectiveness against severe adult alopecia areata.
Read →
RS Oncology Reports New Preclinical Evidence Show RSO-021 Could Halt and/or Revert the Advancement of Severe Mesotheliomas
Latest Hotspot
3 min read
RS Oncology Reports New Preclinical Evidence Show RSO-021 Could Halt and/or Revert the Advancement of Severe Mesotheliomas
20 September 2023
At the 2023 IASLC World Lung Cancer Conference in Singapore, RS Oncology shared a first-of-its-kind PRX3 inhibitor, RSO-021's potential to combat swift mesothelioma tumor progression.
Read →
InnoCare Reveals approval of the Clinical Experiment for ICP-189, Coupled with EGFR Inhibitor Furmonertinib
Latest Hotspot
3 min read
InnoCare Reveals approval of the Clinical Experiment for ICP-189, Coupled with EGFR Inhibitor Furmonertinib
19 September 2023
InnoCare Pharma announced that it received IND approval for a Chinese clinical trial to study the effects of new SHP2 allosteric inhibitor, ICP-189.
Read →
Edgewise Therapeutics commences Phase 1 human trial for EDG-7500, a promising treatment for Hypertrophic Cardiomyopathy and severe Cardiac Diastolic Dysfunction
Latest Hotspot
3 min read
Edgewise Therapeutics commences Phase 1 human trial for EDG-7500, a promising treatment for Hypertrophic Cardiomyopathy and severe Cardiac Diastolic Dysfunction
19 September 2023
Edgewise Therapeutics initiates its first-in-human Phase 1 trial for EDG-7500, the primary clinical contender for Hypertrophic Cardiomyopathy and other severe Cardiac Diastolic Dysfunction conditions.
Read →
The NC318 Phase 2 trial, in Combination with Pembrolizumab, shows clinical activity in treating patients with advanced NSCLC
Latest Hotspot
4 min read
The NC318 Phase 2 trial, in Combination with Pembrolizumab, shows clinical activity in treating patients with advanced NSCLC
19 September 2023
NextCure Inc. and Yale Cancer Center announced Phase 2 trial results today, indicating a combined NC318 and Pembrolizumab regimen is beneficial for advanced non-responsive PD-1 non-small cell lung cancer patients.
Read →
Myeloid Therapeutics begins administering MT-302, a new TROP2-focusing RNA CAR, for advanced or metastatic epithelial tumors
Latest Hotspot
3 min read
Myeloid Therapeutics begins administering MT-302, a new TROP2-focusing RNA CAR, for advanced or metastatic epithelial tumors
19 September 2023
Myeloid Therapeutics, a clinical-stage cancer treatment company, has given the first dose of MT-302 to a patient in a Phase 1 trial for advanced or metastatic epithelial tumors.
Read →
Bioscience Replication begins a Phase 1 Study for its upcoming srRNA Vaccine
Latest Hotspot
3 min read
Bioscience Replication begins a Phase 1 Study for its upcoming srRNA Vaccine
19 September 2023
Replicate Bioscience has administered the first dosage of its RBI-4000 vaccine to a participant.
Read →
Pierre Fabre Laboratories acquires Vertical Bio and its innovative targeted therapy for MET-altered Non-Small Cell Lung Cancer patients
Latest Hotspot
4 min read
Pierre Fabre Laboratories acquires Vertical Bio and its innovative targeted therapy for MET-altered Non-Small Cell Lung Cancer patients
19 September 2023
Pierre Fabre Laboratories takes over Vertical Bio along with its ground-breaking, targeted therapy candidate for patients battling MET-altered Non-Small Cell Lung Cancer.
Read →